SCHEMBL20122698

SCHEMBL20122698

Clc1cc(Br)c2c(c1)c1ccncc1n2CC1CC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ROCK2 O75116 2/20 0.44
GRM2 Q14416 1/20 0.41
DYRK1A Q13627 2/20 0.41
KCNH2 Q12809 1/20 0.41
PTGER4 P35408 2/20 0.38
KDM4C Q9H3R0 1/20 0.37
METAP2 P50579 1/20 0.36
CRHR1 P34998 1/20 0.35
IDO1 P14902 1/20 0.35
MAT2A P31153 1/20 0.35
NFATC1 O95644 1/20 0.34
GSK3B P49841 1/20 0.34
CDK4 P11802 1/20 0.33
CDK6 Q00534 1/20 0.33
KRAS P01116 1/20 0.32
TNKS O95271 1/20 0.32
TNKS2 Q9H2K2 1/20 0.32
CHUK O15111 2/20 0.32
SLC6A2 P23975 2/20 0.31
SLC6A4 P31645 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30664200 0.82 KCNH2 (0.49) ROCK2GRM2DYRK1AKCNH2PTGER4
SCHEMBL20122885 0.82 KCNH2 (0.49) ROCK2GRM2DYRK1AKCNH2PTGER4
SCHEMBL20122848 0.82 ROCK2 (0.42) ROCK2DYRK1AMETAP2CHUKSLC6A2
SCHEMBL20122876 0.81 ROCK2 (0.45) ROCK2DYRK1AKCNH2PTGER4KDM4C
SCHEMBL30664155 0.81 ROCK2 (0.45) ROCK2DYRK1AKCNH2PTGER4KDM4C
SCHEMBL20122886 0.80 DYRK1A (0.46) ROCK2DYRK1AKCNH2PTGER4KDM4C
SCHEMBL21326095 0.80 ROCK2 (0.49) ROCK2DYRK1AKCNH2PTGER4KDM4C
SCHEMBL20122856 0.79 ROCK2 (0.43) ROCK2METAP2MAT2ACHUK
SCHEMBL20122730 0.79 DYRK1A (0.41) ROCK2DYRK1AKCNH2PTGER4KDM4C
SCHEMBL20123075 0.78 DYRK1A (0.45) ROCK2DYRK1AKCNH2PTGER4KDM4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12275733-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders SANOFI (FR) 2025-04-15 US claimed
US-11827633-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders SANOFI (FR) 2023-11-28 US disclosed
US-11827633-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders SANOFI (FR) 2023-11-28 US disclosed
CN-110382496-B Substituted pyrido [3,4-b ] indoles for the treatment of cartilage disorders 赛诺菲 2022-08-09 CN disclosed
US-11130755-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders SANOFI (FR) 2021-09-28 US disclosed
EP-3792262-A1 SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS SANOFI (FR) 2021-03-17 EP disclosed
EP-3535263-B1 SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS SANOFI SA (FR) 2020-09-30 EP disclosed
EP-3318563-A1 SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS SANOFI (FR) 2018-05-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11827633-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders COL2A1, IDO1, COL1A1 ROCK2 1093/4885GRM2 2898/4885DYRK1A 493/4885
US-11130755-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders COL2A1, IDO1, COL1A1 ROCK2 1093/4885GRM2 2898/4885DYRK1A 493/4885
US-12275733-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders COL2A1, IDO1, COL1A1 ROCK2 1093/4885GRM2 2898/4885DYRK1A 493/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.